These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 11343433)

  • 1. The effect of tissue-specific growth patterns of target stem cells on the spectrum of tumours resulting from multistage tumorigenesis.
    Mao JH; Lindsay KA; Mairs RJ; Wheldon TE
    J Theor Biol; 2001 May; 210(1):93-100. PubMed ID: 11343433
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Stochastic modelling of tumorigenesis in p53 deficient mice.
    Mao JH; Lindsay KA; Balmain A; Wheldon TE
    Br J Cancer; 1998; 77(2):243-52. PubMed ID: 9460995
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Murine models of neoplasia: functional analysis of the tumour suppressor genes Rb-1 and p53.
    Clarke AR
    Cancer Metastasis Rev; 1995 Jun; 14(2):125-48. PubMed ID: 7554030
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Germline mutations of the p53 gene].
    Frebourg T
    Pathol Biol (Paris); 1997 Dec; 45(10):845-51. PubMed ID: 9769948
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Li-Fraumeni syndrome].
    Frebourg T
    Bull Cancer; 1997 Jul; 84(7):735-40. PubMed ID: 9339200
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of p53 transgenic mice in the development of cancer models for multiple purposes.
    Lubet RA; Zhang Z; Wiseman RW; You M
    Exp Lung Res; 2000 Dec; 26(8):581-93. PubMed ID: 11195457
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Genetic susceptibility to cancer. ICRP publication 79. Approved by the Commission in May 1997. International Commission on Radiological Protection.
    Ann ICRP; 1998; 28(1-2):1-157. PubMed ID: 10406427
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours.
    Donehower LA; Harvey M; Slagle BL; McArthur MJ; Montgomery CA; Butel JS; Bradley A
    Nature; 1992 Mar; 356(6366):215-21. PubMed ID: 1552940
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nucleotide excision repair- and p53-deficient mouse models in cancer research.
    Hoogervorst EM; van Steeg H; de Vries A
    Mutat Res; 2005 Jul; 574(1-2):3-21. PubMed ID: 15914203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [p53 transgenic and knockout mice].
    Oda H
    Nihon Rinsho; 2000 Jun; 58(6):1250-4. PubMed ID: 10879049
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The difference between benign and malignant tumours explained with the 4-mutation paradigm for carcinogenesis.
    Koten JW; Neijt JP; Zonnenberg BA; Den Otter W
    Anticancer Res; 1993; 13(4):1179-82. PubMed ID: 8352541
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Spontaneous and carcinogen-induced tumorigenesis in p53-deficient mice.
    Harvey M; McArthur MJ; Montgomery CA; Butel JS; Bradley A; Donehower LA
    Nat Genet; 1993 Nov; 5(3):225-9. PubMed ID: 8275085
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Role of transgenic mice in identification and characterization of tumour suppressor genes.
    Sharan SK; Bradley A
    Cancer Surv; 1995; 25():143-59. PubMed ID: 8718516
    [TBL] [Abstract][Full Text] [Related]  

  • 14. INGN 201: Ad-p53, Ad5CMV-p53, adenoviral p53, p53 gene therapy--introgen, RPR/INGN 201.
    Drugs R D; 2007; 8(3):176-87. PubMed ID: 17472413
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Most spontaneous tumors in a mouse model of Li-Fraumeni syndrome do not have a mutator phenotype.
    Hill KA; Buettner VL; Heidt A; Chen LL; Li W; Gonzalez KD; Wang JC; Scaringe WA; Sommer SS
    Carcinogenesis; 2006 Sep; 27(9):1860-6. PubMed ID: 16597646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Oncogenic co-operation in beta-cell tumorigenesis.
    Pelengaris S; Khan M
    Endocr Relat Cancer; 2001 Dec; 8(4):307-14. PubMed ID: 11733227
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Gain of function of a p53 hot spot mutation in a mouse model of Li-Fraumeni syndrome.
    Lang GA; Iwakuma T; Suh YA; Liu G; Rao VA; Parant JM; Valentin-Vega YA; Terzian T; Caldwell LC; Strong LC; El-Naggar AK; Lozano G
    Cell; 2004 Dec; 119(6):861-72. PubMed ID: 15607981
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A detailed study of loss of heterozygosity on chromosome 17 in tumours from Li-Fraumeni patients carrying a mutation to the TP53 gene.
    Varley JM; Thorncroft M; McGown G; Appleby J; Kelsey AM; Tricker KJ; Evans DG; Birch JM
    Oncogene; 1997 Feb; 14(7):865-71. PubMed ID: 9047394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of genetic background on tumorigenesis in p53-deficient mice.
    Donehower LA; Harvey M; Vogel H; McArthur MJ; Montgomery CA; Park SH; Thompson T; Ford RJ; Bradley A
    Mol Carcinog; 1995 Sep; 14(1):16-22. PubMed ID: 7546219
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In silico saturation mutagenesis of cancer genes.
    Muiños F; Martínez-Jiménez F; Pich O; Gonzalez-Perez A; Lopez-Bigas N
    Nature; 2021 Aug; 596(7872):428-432. PubMed ID: 34321661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.